Tuesday, September 30, 2014

Rimini Street Revenue for Oracle E-Business Suite and Oracle Database Support More than Triples

Rimini Street Q3 Results Have Already Exceeded Plan; Nearly Doubled Client Numbers and Global Contracts Demonstrate Strong Momentum

SAN FRANCISCO - Tuesday, September 30th 2014 [ME NewsWire]

Oracle OpenWorld 2014

(BUSINESS WIRE) -- Rimini Street, Inc., the leading independent provider of enterprise software support for SAP AG’s (NYSE:SAP) Business Suite and BusinessObjects software and Oracle Corporation’s (NYSE:ORCL) Siebel, PeopleSoft, JD Edwards, E-Business Suite, Oracle Database, Oracle Middleware, Hyperion and Oracle Retail software, today announced that combined revenue for its Oracle E-Business Suite (EBS) and Oracle Database and Middleware (Oracle Technology) product lines surged more than three-fold in the trailing 12 months, growing by 248 percent, and the number of signed clients for these services nearly doubled during the same period, to over 180, indicating increased adoption of Rimini Street independent support among global entities and helping to fuel the Company’s substantial growth since Oracle OpenWorld 2013.

Global Investment in Oracle EBS and Oracle Technology Support Capabilities

Rimini Street has continued to invest in the development of resources, processes and technical capabilities to successfully deliver support globally for its most complex Oracle clients. Recently, Rimini Street announced the formal expansion of its Oracle Technology support offering to include Oracle Middleware products. Today, the Company supports Oracle Database and Middleware products stand-alone, without any required application support pairing.

As a result, the Company has experienced rapid growth and adoption worldwide for Oracle EBS and Oracle Technology. In the past 12 months, Rimini Street has nearly doubled its number of Oracle EBS and Oracle Technology clients, including a wide array of organizations from midmarket to very large, complex Fortune 500 multinationals, including, for example, one client who is operating more than 600 mission-critical Oracle database servers around the world.

“Choosing Rimini Street over Oracle to support our mission-critical EBS platform has enabled us to regain control over our upgrade timetable, provided superior support and liberated significant budget which we’ve reinvested into growth for the business,” said Tom Grooms, CIO, The Valspar Corporation. “My only regret is that I didn’t move to Rimini Street years earlier.”

Strong Growth “Business as Usual” for Rimini Street

Since Rimini Street launched support nearly 10 years ago, the Company has experienced strong and steady demand for its independent support services among Oracle licensees worldwide, across every product line it supports. In the past 12 months, an increase in demand across Oracle product lines, indicate licensees are seeking and choosing to drive greater value from their annual software support dollars while foregoing ERP upgrades and costly migrations to new platforms, such as Oracle’s Fusion Applications.

With new software platforms uncertain, and costly incremental upgrades of little value to many licensees, many Oracle licensees are instead electing to deploy innovative applications “around the edges of their current core Oracle ERP systems” in a hybrid deployment model. Such a model moves from the traditional large, integrated single-vendor product suite to a hybrid IT landscape of core transaction “systems of record” integrated with best-of-breed software applications, and will include a combination of on-premise and Cloud application delivery models.

“The market has spoken and it clearly wants a choice of support providers and program options. Oracle and SAP licensees are increasingly seeking out more value-driven and responsive support that will successfully cover today’s multi-vendor, hybrid deployment model,” said Seth Ravin, Rimini Street CEO. “As the software industry continues to seek new ways to extract additional fees out of existing licensees, Rimini Street remains focused on helping its clients achieve their IT and business objectives by maximizing the return on their existing software investments and leveraging Rimini Street’s award-winning support offerings.”

About Rimini Street, Inc.

Rimini Street is the leading independent provider of enterprise software support services. The company is redefining enterprise support services with an innovative, award-winning program that enables Oracle and SAP licensees to save up to 90 percent on total support costs over a decade, including saving 50 percent on their annual support fees. Clients can remain on their current software release without any required upgrades or migrations for at least 15 years after switching to Rimini Street. Hundreds of clients, including global, Fortune 500, midmarket, and public sector organizations from across a broad range of industries have selected Rimini Street as their trusted, independent support provider. To learn more, please visit www.riministreet.com or call within the USA 888-870-9692 or internationally +1 702-839-9671.

Rimini Street and the Rimini Street logo are trademarks of Rimini Street, Inc. All other company and product names may be trademarks of their respective owners. Copyright © 2014. All rights reserved.


Rimini Street, Inc.

Alma Park, 323-229-7282


Permalink: http://www.me-newswire.net/news/12267/en

French Police praises UAE Security Authorities’ Efficiency in Applying the Highest International Standards

During the graduation of a “Human Rights” course in Abu Dhabi

ME NewsWire

Abu Dhabi, United Arab Emirates - Sunday, September 28th 2014

Major General Marc Boudet, from the General Inspectorate of the French police, praised the efficiency of the police and security authorities in the UAE, which implement international best standards in providing services to community members, boosting safety and security and improving the skills of police staff members. He noted that the UAE stands today amongst the leading countries in respect for human rights; thanks to its advanced security bodies, which apply international best standards and specifications. He also praised the efforts of Abu Dhabi Police and their staff members who enjoy a vast experience and a solid knowledge base in this area, as well as their diligent efforts to achieve the highest standards of excellence.

These remarks were made by Major General Marc Boudet, during the ceremony held on Thursday at the Hilton Abu Dhabi Corniche Hotel by the Training Department at Abu Dhabi Police’s Human Resources Directorate General, to celebrate the graduation of a course titled “Human rights and ethics management in daily work”. A total of 20 staff members from Abu Dhabi Police’s various departments took part in the course, which was delivered by Major General Marc Boudet, from the General Inspectorate of the French police, who is an expert on work ethics within the police force,   the conduct of police members and dealing with international organizations concerned with human rights; in addition to Colonel Pierre Francois Guerin, from the French police.

Major General Boudet said that the course was designed to exchange and enhances expertise between both the UAE and French police; with respect to practices related to police work ethics and human rights; particularly in this day and age, when security forces all over the world suffer severe pressure in the area of respect for human rights. He explained that police bodies across the world face accountability for their observance and respect for human rights.

For his part, Colonel Pierre Francois Guerin from the French police noted that visitors to the UAE enjoy a deep sense of security and safety; thanks to the unstinting efforts of police and security forces in the country, which endeavor to achieve the highest levels of security and safety for all.

In conclusion, Lieutenant Colonel Saleh Saeed Al Amoudi, International Cooperation Branch Manager at the Training Department, indicated that the training courses carried out by the Human Resources Directorate General, represented by the Training Department, aims mainly to improve police work and provide the best security services through a highly qualified police body. “The department resorts to the best international experts to provide an overview of their scientific and practical experiences to police staff members at the Abu Dhabi Police GHQ,” he said.

For more information about:

The Ministry of Interior, please click HERE

Abu Dhabi Police, please click HERE

Follow us and check our Social Media feeds on: YouTube, Facebook and Twitter

The Arabic-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the Arabic-language text, which is the only version of the text intended to have legal effect.


The UAE Minister of Interior's General Secretariat, Tactical Affairs and Security Media Department

Abu Dhabi Police GHQ - Security Media

Chris Cron +971-(0)-50-987-1317

E-mail: cron.media@hotmail.com

Permalink: http://www.me-newswire.net/news/12235/en

General Cable Withdraws Proposed Offering of Senior Unsecured Notes

HIGHLAND HEIGHTS, Ky. - Monday, September 29th 2014 [ME NewsWire]

(BUSINESS WIRE)-- General Cable Corporation (NYSE: BGC) (the “Company”) today announced that in light of current market conditions it has decided not to proceed with its previously announced offering of $250 million of senior unsecured notes due 2019 at this time.

“Uncertain and weak overall conditions in the high yield debt market led us to conclude that the proposed offering of senior unsecured notes would not be in the best interest of shareholders under terms currently available,” stated Gregory B. Kenny, President and Chief Executive Officer. "The senior unsecured note offering and the intended use of proceeds was an opportunity to address the maturity of the 2015 floating rate notes and prefund the restructuring program. However, we have the flexibility with respect to the timing of such an offering as we maintain the liquidity under our existing asset-based revolving credit facility to fund operations and capital requirements. We will continue to monitor debt markets and may return to the market when conditions are more favorable.”

General Cable (NYSE:BGC), a Fortune 500 Company, is a global leader in the development, design, manufacture, marketing and distribution of copper, aluminum and fiber optic wire and cable products and systems for the energy, industrial, specialty, construction and communications markets.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve risks and uncertainties, predict or describe future events or trends and that do not relate solely to historical matters. Forward-looking statements include, among others, expressed expectations with regard to the following: “believe,” “expect,” “may,” “will,” “anticipate,” “intend,” “estimate,” “project,” “plan,” “assume,” “seek to” or other similar expressions, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those discussed in forward-looking statements as a result of factors, risks and uncertainties over many of which we have no control. These factors include, but are not limited to, the risks detailed from time to time in the Company’s filings with the Securities and Exchange Commission (“SEC”), including but not limited to, our annual report on Form 10-K filed with the SEC on March 3, 2014, and subsequent SEC filings. You are cautioned not to place undue reliance on these forward-looking statements. General Cable does not undertake, and hereby disclaims, any obligation, unless required to do so by applicable securities laws, to update any forward-looking statements as a result of new information, future events or other factors.


General Cable Corporation

Len Texter, Vice President, Investor Relations, 859-572-8684

Permalink: http://www.me-newswire.net/news/12265/en

Toshiba Starts Vegetable Production at Toshiba Clean Room Farm Yokosuka

—Aims to produce 3 million bags of vegetables a year—

TOKYO - Tuesday, September 30th 2014 [ME NewsWire]

(BUSINESS WIRE) -- Toshiba Corporation (TOKYO: 6502) today announced that it has begun production of vegetables at the Toshiba Clean Room Farm Yokosuka, a plant factory in Yokosuka, Kanagawa prefecture. Shipment of the first crop is scheduled for the end of October.

Located in a formerly idle facility, Toshiba’s closed-type plant factory uses state-of-the-art technology to raise crops and operates under almost aseptic conditions*1. Toshiba aims for annual output of three million bags (one bag is equivalent to a head of lettuce) of leaf lettuce, baby leaf greens, spinach, mizuna and herbs per, and targets annual sales target of 300 million yen.

Plant factories grow vegetables in close to sterile conditions in almost germ-free cleanrooms. Minimizing the entry of germs and the damage that they can do considerably extends the freshness and shelf-life of vegetables, a major concern for retailers of cut vegetables and salads. Toshiba will promote sales to supermarkets, convenience stores, delicatessens and restaurants.

The factory is equipped with a wide range of technologies and know-how from across Toshiba Group, including fluorescent lighting with an output wavelength optimized for vegetable growth; air-conditioning systems that maintain constant temperature and moisture level; remote monitoring systems to track growth; and sterilization systems for packing materials. The production management system is based on that utilized for semiconductor device production.

In order to increase sales in this new business, Toshiba is also considering construction of a large-scale plant factory outside Japan, and the sale of equipment for plant factory applications within FY2014.

Toshiba is promoting a healthcare business throughout the world to support the development of a society where people can lead healthier and happier lives. Toshiba Group is also promoting “New Concept Innovation” in order to create new value by combining the Group’s wide-ranging technologies. The aim is to offer unique products and services and to develop new sales channels to further strengthen business operations.



An environment where germs are found on vegetables at about 1/1000th the level typical for vegetables grown in soil.

Overview of Toshiba Clean Room Farm Yokosuka

Address: 1-201-1 Funakoshi-cho, Yokosuka, Kanagawa Total floor area: Approximately 1,969 square meters Vegetables cultivated: Lettuce, baby leaf spinach, mizuna, herbs Production scale: 3 million bags a year (lettuce equivalent)

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50952154&lang=en


Toshiba Corporation
Masumi Fukuoka / Tatsuro Oishi, +81-3-3457-2100
Public Relations & Investor Relations Office
Corporate Communications Division

Permalink: http://www.me-newswire.net/news/12269/en

ZTE Customer E-Plus Ranked Second in Mobile Network Test

ZTE helps E-Plus to modernise its UMTS network and deliver LTE equipment

DÜSSELDORF, Germany - Tuesday, September 30th 2014 [ME NewsWire]

(BUSINESS WIRE) -- ZTE Deutschland GmbH, a subsidiary of ZTE Corporation the leading global provider of telecommunications equipment, network solutions and mobile devices, has announced that its customer E-Plus has come second place in a comprehensive network test that was conducted by the German telecom magazine COMPUTER BILD. E-Plus’s network which was modernised with core network, Universal Mobile Telecommunications System (UMTS) and LTE equipment by ZTE, was placed in the top two due to its recent expansion and excellent performance of its UMTS network, as well as fast download speeds.

E-Plus and ZTE entered into a strategic partnership in 2009, when E-Plus chose ZTE as leading equipment supplier for E-Plus’s mobile network. Since the beginning of 2014, ZTE has also maintained and operated its network. Those who voted for E-Plus highlighted the speed of the network and its exceptional user-experience. The results of the vote by CHIP reader’s choice have now been confirmed by COMPUTER BILD’s network test in which E-Plus outperformed its competitors. In some areas of Germany, E-Plus offered a download speed that averaged 50 percent faster compared to those offered by its competitors, with speeds of 9.43 megabytes per second (Mbps) in the UMTS network and 30.89 Mbps in the LTE standard network. The E-Plus network was also praised in this test for its dense UMTS network coverage (98.8 percent of the tested area), the highest successful network browse rate and the second fastest webpage opening speed of 1.8 seconds in its UMTS network.

COMPUTER BILD’s 2014 network test was conducted by its own network test-application. According to the publication, the test combines data from more than 61,000 users who downloaded the app on a tablet or smartphone. The network test was based upon a total of approximately 18.5 million measurements of data speeds as well as approximately 16 million call minutes.

“Recognizing our customers’ needs, ZTE continues to introduce cutting-edge technology which enhances network capacity and enable operators to provide high-quality networks. COMPUTER BILD’s evaluation of the German E-Plus shows that ZTE has a strong technical capability to support operators to build world-class networks,” said Li Jun, Managing Director of ZTE Deutschland GmbH.

About ZTE

ZTE is a publicly-listed global provider of telecommunications equipment and network solutions with the most comprehensive product range covering virtually every telecommunications sector, including wireless, access & bearer, VAS, terminals and professional services. The company delivers innovative, custom-made products and services to over 500 operators in more than 140 countries, helping them to meet the changing needs of their customers while growing revenue. ZTE commits 10 per cent of its annual revenue to research and development and has leadership roles in several international bodies devoted to developing telecommunications industry standards. ZTE is committed to corporate social responsibility and is a member of the UN Global Compact. The company is China’s only listed telecom manufacturer that is publicly traded on both the Hong Kong and Shenzhen Stock Exchanges (H share stock code: 0763.HK / A share stock code: 000063.SZ). For more information, please visit www.zte.com.cn.

ZTE Corporation
Margrete Ma, +86 755 26775207

AxiCom PR
William de la Bedoyere, +44 (0)20 8392 8074

Permalink: http://me-newswire.net/news/12266/en

Meet Amelia: IPsoft's New Artificial Intelligence Platform Interacts Like a Human

New artificial intelligence computing platform set to transform the global workforce

NEW YORK - Monday, September 29th 2014 [ME NewsWire]

 (BUSINESS WIRE) -- IPsoft today announced a new artificial intelligence platform named “Amelia” that makes it possible to automate knowledge work across a broad range of functions. Exposed to the same information as any new hire, she can quickly apply her knowledge to solve queries in a wide range of business processes. With Amelia able to shoulder the burden of tedious, often laborious tasks, she partners with human coworkers to achieve new levels of productivity and service quality.

Whereas many other technologies demand that humans adapt their behavior in order to interact with ‘smart machines’, Amelia is intelligent enough to interact like a human herself. This equips her to deliver a top quality customer experience for any of the businesses in which she is deployed.

Amelia learns using the same natural language manuals as her colleagues but in a matter of seconds. She understands the full meaning of what she reads rather than simply recognizing individual words. This involves understanding context, applying logic and inferring implications. Independently, rather than through time intensive programming, Amelia creates her own process map of the information she is given so that she can work out for herself what actions to take depending on the problem she is solving. Just like any smart worker she learns from her colleagues and by observing their work, she continually builds her knowledge.

In a fraction of the time it takes traditionally to train someone in a new role, Amelia is able to perform at a high level. What is more, as she already speaks more than 20 languages she is able to support international operations with ease. Her core knowledge of a process needs only to be learned once for her to be able to communicate with customers in their language.

“When investigating smart solutions, we must first analyze what it means to be intelligent. Intelligence is the ability to acquire and apply knowledge. If a system claims to be intelligent, it must be able to read and understand documents, and answer questions on the basis of that. It must be able to understand processes that it observes. It must be able to solve problems based on the knowledge it has acquired. And when it cannot solve a problem, it must be capable of learning the solution through noticing how a human did it. Amelia is that mensa kid, who personifies a major breakthrough in cognitive technologies,” said Chetan Dube, Chief Executive Officer, IPsoft. “Amelia will allow people to indulge in more creative forms of expression, as opposed to doing routine business process tasks. This platform will free us from the mundane, disrupting industries in the way that machines have previously transformed manufacturing and agriculture. We’re going to have to rethink work by redefining existing roles and identifying new ones.”

Much like machines transformed agriculture and manufacturing, cognitive technologies will drive the next evolution of the global workforce. In the future, companies will compete in the digital economy with a digital workforce that comprises a balance of human and virtual employees. Gartner predicts that by 2017, managed services offerings leveraging autonomics and cognitive platforms like Amelia will drive a 60 percent reduction in the cost of services1. That’s because Amelia is uniquely positioned to be an extension of the existing workforce, enabling organizations to apply human talent to higher level tasks requiring creativity, curiosity and innovation. The technology is already being piloted within a number of Fortune 1000 companies and IPsoft expects to announce new customers and prominent industry partners before the end of the year.

Why Amelia?

Named after American aviator and pioneer Amelia Earhart, IPsoft has been working on this technology for 15 years with the goal to build a platform that doesn’t simply mimic human thought processes but can comprehend the underlying meaning of what is communicated just like a human. In much the same way we learned to fly by studying the science of flight rather than building something that flaps its wings like a bird, Amelia can think in a human way rather than simply mimic human thought processes, marking a major breakthrough in cognitive technology. Amelia builds a mind map that grasps concepts and the relationships between them. As a result she appreciates the context and implications of what is being communicated.

Real World Applications for Amelia’s Technology

Because Amelia learns just as a new employee would, she can be deployed in any business scenario. Currently, she is being piloted in the areas including: technology help desks, procurement processing, financial trading operations support and expert advisor for field engineers. In each of these environments, she learns not only from reading existing manuals and situational context but also by observing and working with her human colleagues and discerning for herself a map of the business processes being followed. She can provide valuable, smart recommendations and solutions to her human coworkers and customers.

In a help desk situation, Amelia can understand what a caller is looking for, ask questions to clarify the issue, find and access needed information and determine which steps to follow in order to solve the problem. As a knowledge management advisor, she can help engineers working in remote locations and unable to carry with them detailed manuals. By exchanging information with Amelia, she can diagnose the cause of failed machinery and guide them towards the best steps to rectifying the problem.

For more information about Amelia, including a video demonstration, please visit http://www.ipsoft.com/amelia.

About IPsoft

IPsoft automates IT and business processes for enterprises across a wide range of industries. Through its portfolio of world leading autonomic and cognitive solutions it provides services that allow its clients to secure competitive advantage. Headquartered in New York City, IPsoft has offices in ten countries across the world and serves more than 500 of the world’s leading brands directly as well as more than half of the world’s largest IT services providers. For more information please visit www.ipsoft.com.

1 “Predicts 2014: Business and IT Services Are Facing the End of Outsourcing as We Know It,” Gartner, 24 January 2014

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50950710&lang=en


IPsoft contact (US)

Weber Shandwick

Joseph Gallo, +1 212-445-8247



IPsoft contact (UK)

Weber Shandwick

Benjamin Pfeffer, +44 (0) 207 067 0461


Permalink: http://www.me-newswire.net/news/12242/en

Monday, September 29, 2014

CORRECTION & REPLACEMENT // Zayed Future Energy Prize Announce 2015 Finalists

Selection Committee shortlist 31 finalists in the lead for the 2015 award

Abu Dhabi, United Arab Emirates - Monday, September 29th 2014 [ME NewsWire]

31 finalists have been shortlisted for the 2015 edition of the Zayed Future Energy Prize, the world’s foremost award for innovation in renewable energy and sustainability.

The Prize’s Selection Committee met in Abu Dhabi on 16-17 September to discuss and evaluate 59 entries that had earlier been shortlisted by the Review Committee in five categories: Large Corporation, Small and Medium Enterprise (SME), Non-Profit Organisation (NPO), Lifetime Achievement and Global High Schools.

His Excellency Dr Sultan Ahmed Al Jaber, Director-General of the Zayed Future Energy Prize, said: “The Zayed Future Energy Prize is yet another reflection of our wise leadership’s limitless drive towards supporting sustainable growth, not just in the UAE but the world over. The Prize embodies the vision of our leadership for a more sustainable future, where renewable energy plays a significant role in the advancement of energy security, economic and social development, and the alleviation of poverty.”

“The Selection Committee has identified the breakthrough ideas, technologies and academic proposals, that will positively influence the world, delivering access to energy and water to millions, championing sustainability and the deployment of renewable energy, and creating jobs and educational opportunities within the clean energy space.” added Dr Al Jaber.

The finalists for the 2015 Large Corporation category demonstrate leadership in energy efficient products, large scale utilities, energy storage and solar generation, reflecting a broader trend of increasing global demand for renewable energy. Developments in both commercial and consumer appetites for sustainable products have influenced some large corporations to adopt renewable energy and sustainability practices into their business models as a means of revenue generation and enhanced energy efficiency.

The Selection Committee also recognised SMEs and NPOs for their work to commercialise off-grid solar in poor households in East Africa and Asia. As the growth of off-grid solar sees rapid adoption around the world in both developing and developed markets, innovation sees practical application in an effort to deploy resources; from using simple plastic bottles made from basic household materials in rooftops to radically improve lighting conditions, to supplying a total of 230,000 solar home systems and 1.2m solar lanterns in communities without grid access.

Finalists for the 2015 Zayed Future Energy Prize are, Enel Green Power, First Solar, IKEA and Panasonic in the Large Corporation category; Electriciens sans Frontières, Liter of Light, Practical Action, SolarAid, and World Resources Institute for the Non-Profit Organisations category; and Econation, M-Kopa, and SELCO, have been identified as finalists in the Small and Medium Enterprise category.

Finalists for the 2015 Global High Schools category across the five geographical regions include, Abaarso School of Science and Technology, Alliance Girls High School, and Waterford Kamhlaba (Africa); DGEyC E.S.E.T. Nº 4 El Palomar, Colegio Roosevelt, Munro Academy (Americas); Amra Bint Abdul Rahman Secondary School for Girls, Royal College, Rishi Valley Education Centre and Addu High School (Asia), and Melbourne Girls School, Lumé Rural Training Center, and Cashmere High School (Oceania); with a single school identified as a potential finalist for the European region.

The Selection Committee also identified 5 individuals as finalists for the Lifetime Achievement category.

Marie-José Nadeau, Chair of the World Energy Council and Vice-Chair of the Zayed Future Energy Prize Selection Committee, said: “With nearly 1.2 billion people in the world living without energy access, the Prize has never been more crucial in the deployment of socially responsible solutions to one of the world’s most important challenges:  How to balance the Energy Trilemma and simultaneously deliver a secure, affordable, and environmentally sustainable energy system. The Zayed Future Energy Prize is an impressive initiative, not only in terms of global outreach and visibility for the UAE, but in its strategic and philanthropic approach to affecting change in a growing sector of the energy market. The Selection Committee has recommended very strong finalists for the 2015 award. The Jury has a difficult task ahead of them to make the final decision in each category. We believe whoever they choose, whether organisation, individual or school, will be a very sound choice as a winner of this valuable Prize.”

In the final phase of evaluation, the contenders are set to be presented to the Prize Jury on 20 October. Winners of the seventh edition will be announced at the Zayed Future Energy Prize awards ceremony scheduled for 19 January, 2015, as part of the annual Abu Dhabi Sustainability Week.

The Selection Committee comprises international energy experts in academia, research and policy advocacy, technology, energy access and security in renewables and sustainability. Chaired by Dr. Behjat Al Yousuf, Dean of Students, Masdar Institute (MI), Professor of Practice Engineering Systems Management, the Selection Committee includes Marie-Jose Nadaeu, Vice-Chair of the Zayed Future Energy Prize Selection Committee and Chair of the World Energy Council, Executive Vice President Corporate Affairs and Secretary General Hydro Quebec; Roger Ballentine, President, Green Strategies; Dr. Olaf Goebel, Professor of Energy Engineering and Renewable Energies, University of Applied Science in Hamm and Lippstadt; Dr. Steve Griffiths, Executive Director of Institute Initiatives Professor of Practice, MI; Anup Jacobs, Director of Masdar Capital; Richenda Van Leeuwen, Executive Director, Energy and Climate, Energy Access Initiative, United Nations Foundation; Dalya Al Muthanna, President and CEO, General Electric Gulf Region; Gunter Pauli, Author of ‘The Blue Economy’ and Founder of Zero Emissions Research Initiative; Jonathon Porrit, Co-founder, Forum for the Future; Maha Salem Jabour, Advisor to Director General, Abu Dhabi Education Council; David Sandalow, Inaugural Fellow, Centre on Global Energy Policy, Columbia University; Gauri Singh, Director, Country Sustainability and Partnerships, International Renewable Energy Agency (IRENA)  Professor Ad Van Wijk, Sustainable Energy Entrepreneur and Professor of Future Energy Systems at the Delft University of Technology and Yukari Yamashita, Board Member, Director Energy Data and Modeling Center, Institute of Energy Economics, Japan (IEEJ).

For more information on the prize, please visit www.ZFEP.ae

Stay connected at www.facebook.com/TZFEP and www.twitter.com/zfep


Alessandra Bell

Communications Consultant, +971 555 092736


Toshiba Concludes a Memorandum of Understanding with Ethiopian Electric Power on Geothermal Power Generation

TOKYO - Monday, September 29th 2014 [ME NewsWire]

(BUSINESS WIRE)--Toshiba Corporation (TOKYO: 6502) today announced that the company has concluded a memorandum of understanding (MOU) with Ethiopian Electric Power on a comprehensive partnership in geothermal power that will see the parties collaborate in power generation projects and personnel development.

Ethiopian Electric Power (EEP), a publicly owned utility, engages in the development of geothermal resources and the construction of power plants. Through the partnership with EEP, Toshiba will draw on its long-standing experience and expertise in geothermal systems to contribute to projects in Ethiopia. More specifically, the company will develop and manufacture major equipment, create operation and management guidelines, cooperate in personnel development, and start a waste heat utilization business.

Ethiopia is geothermal rich, with resources estimated at equivalent to 6,000 megawatts. However, this potential has yet to be explored and developed, and over 90 percent of the country’s electricity is from hydropower sources. Looking to the future, Ethiopia plans to increase its current installed generating capacity of 2,268 megawatts to 37,000 megawatts by 2037, and the development of geothermal power will play a significant role in reaching that target.

Toshiba commands the world’s largest market share for geothermal equipment with 24% of total installed capacity*. The company delivered Japan’s first geothermal turbine and generator, with a capacity of 20 megawatts, to the Matsukawa Geothermal Power Plant in Iwate in 1966. Since then, Toshiba has delivered 52 geothermal turbines and generators with a total installed capacity of approx. 2,800 megawatts to North America, Southeast Asia, Iceland and elsewhere around the world.

Toshiba will continue to promote various forms of renewable energy generation in the global market, including geothermal, wind, hydro and photovoltaic energy, to contribute to a reliable supply of renewable energy worldwide.

* Toshiba data

About Toshiba

Toshiba Corporation, a Fortune Global 500 company, channels world-class capabilities in advanced electronic and electrical product and systems into five strategic business domains: Energy & Infrastructure, Community Solutions, Healthcare Systems & Services, Electronic Devices & Components, and Lifestyles Products & Services. Guided by the principles of The Basic Commitment of the Toshiba Group, “Committed to People, Committed to the Future”, Toshiba promotes global operations towards securing “Growth Through Creativity and Innovation”, and is contributing to the achievement of a world in which people everywhere live safe, secure and fulfilled lives.

Founded in Tokyo in 1875, today’s Toshiba is at the heart of a global network of over 590 consolidated companies employing over 200,000 people worldwide, with annual sales surpassing 6.5 trillion yen (US$63 billion).

To find out more about Toshiba, visit www.toshiba.co.jp/index.htm


Toshiba Corporation

Yuu Takase, 81-3-3457-2105

Corporate Communications Division

Public Relations & Investor Relations Office


Fax: 81-3-5444-9202


Permalink: http://www.me-newswire.net/news/12257/en

ZTE to Strengthen Its Stake in the Middle East’s Smartphone Market

Company unveils three flagship smartphones Grand SII LTE, Nubia Z5S Mini and Blade Vec 4G at Gitex Shopper Autumn 2014

DUBAI, UAE - Monday, September 29th 2014 [ME NewsWire]

Gitex Shopper Autumn 2014

(BUSINESS WIRE)-- ZTE, one of the global leaders in the mobile handset manufacturing industry, launches its three new smartphone devices at this year’s Gitex Shopper and has announced its strategic partnership with Global Distribution FZE, a leading distributor of IT and Mobility products as the exclusive distributor of ZTE-Smartphone products in the UAE.

Aiming to take on a bigger market share in the Middle East smartphone market, ZTE is showcasing its flagship products – Grand SII LTE, Nubia Z5S Mini and Blade Vec 4G – to the region for the first time. Deemed to be a ‘game changer’ in the region’s smartphone segment, the launch of these products is part of the global telecommunications company’s strategic efforts to strengthen its market presence in the Middle East.

“The UAE, one of the leaders in the global telecommunication industry with sophisticated growth in 4G network market, is one of our most concerned markets. In order to strengthen ZTE’s pioneer position in the GCC market, we see Dubai as an access to integrate into the wider Middle East & North Africa (MENA) region. We will launch premium products in this region through open channel and operator channel,” said Ning Tian, Regional Director of MENA, ZTE Mobile Device.

ZTE’s flagship revolutionary 4G smartphones launched at Gitex Shopper are innovative with top-of-the-line features. The Grand SII LTE, known for its exceptional processing speed, is one of the world’s fastest 4G smartphones. It is paired with the new Qualcomm Snapdragon 801 processor. It has a 5.5-inch full HD, 1080p display, providing a crystal clear display.

Running on Android 4.3 OS, the Grand SII LTE is packed with one unique security option that enables users to unlock their handset with their voices, using a phrase of their choice. It also has improved audio features for clearer calls and a 13-megapixel camera, a 2-megapixel front-facing camera for better quality photos.

The Nubia Z5S Mini appeals to customers’ needs for aesthetic value with its stylish look designed by an Italian artist Stefano Giovannoni. It is also packed with 4G chipset MSM8926 Quad core 1.2Ghz and is equipped with a 4.7-inch, 720p touch screen, one of Sharp’s excellent IGZO panels. It has 4G LTE connectivity and a MicroSD card slot to increase the 16GB of internal memory.

The Nubia Z5S Mini has 13 megapixels on the rear, and is equipped with a backside illuminated sensor with an F2.2 aperture, all hidden behind a sapphire lens, along with an LED flash and a 5-megapixel front camera. Offering a choice of three modes, including an auto and a pro mode for improved control, this ZTE smartphone will satisfy the needs of selfie and groufie lovers.

Meanwhile, featuring a quad-core Qualcomm processor and a crisp TFT 5-inch display, ZTE Blade Vec 4G is just 7.8mm thick. The back of the device is made of glass fibre with special stripes design, making it fashionably scratch-proof. This 4G smartphone has a 1280 x 720 display and an 8MP camera and runs on Android 4.4 KitKat.

“There has been a tremendous growth across the global smartphone industry particularly in Middle Eastern countries such as the UAE and Saudi Arabia. This region – expected to account for the second largest smartphone population in the world, according to International Data Corporation (IDC)’s Quarterly Mobile Phone Tracker – is definitely one of the primary target markets for ZTE and we are committed to establish our brand in the smartphone market by providing products that are suitable to consumers’ needs,” said Tian.

Tao Jiang, Vice President of EMEA (Europe, Middle East & Africa), ZTE Mobile Device added, “While ZTE is already prominent in many countries in terms of our terminal products that help build and sustain infrastructures, we are also optimistic that our new and innovative smartphones will also gain ground and attain a considerable share in the smartphone and mobile market in the coming years in UAE.”

ZTE aims to ship 60 million smartphones in 2014 and expects revenue from the terminal device unit to grow more than 15 percent in 2014 from a year earlier.

These three flagship products along with ZTE’s new line of smartphones will be displayed at their stand at Gitex Shopper, happening from 27th September to 4th October at Dubai World Trade Centre.

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50951095&lang=en


ZTE Corporation

Eva Chen, +86 21 68897511



Waggener Edstrom Communications

Laura Liu, +86 10 59001242


Permalink: http://me-newswire.net/news/12256/en

AHF Milestone: 350,000 People in 36 Countries Now Receiving AIDS Care and Treatment

LOS ANGELES. - Saturday, September 27th 2014 [ME NewsWire]

350,000-patient benchmark also represents one-third of AHF’s own commitment to caring for one million patients by 2020 as part of the 20X20 Campaign—a worldwide effort to provide AIDS care to 20 million by 2020.

In the U.S., where AHF first launched in 1987, the nonprofit now provides lifesaving treatment in 41 clinics in 13 states and the District of Columbia; Worldwide, AHF operates 222 additional AIDS free treatment clinics.

(BUSINESS WIRE) AIDS Healthcare Foundation (AHF), the largest global AIDS organization, is pleased to announce that is has reached another inspirational milestone in the history of the Foundation: as of this week, AHF is now caring for more than 350,000 patients in 36 countries around the world.

“All of us at AHF are very proud to have reached this significant milestone and want to express our gratitude to the staff, partners, patients, supporters and all members of the AHF community around the world for making it possible,” said Michael Weinstein, President of AIDS Healthcare Foundation. “While we take a moment to mark this a landmark accomplishment, this moment should also serve as a reminder of those who remain without access to lifesaving HIV/AIDS treatment and of how much work there is still to be done. We will not stop until every person living with HIV is receiving treatment.”

“Our 350,000-patient benchmark also represents one-third of AHF’s personal and professional commitment to caring for one million HIV/AIDS patients by the year 2020 as AHF’s overall commitment to the 20X20 Campaign—a worldwide advocacy effort to provide lifesaving AIDS care to 20 million individuals by 2020,” said Terri Ford, Chief of Global Policy and Advocacy for AIDS Healthcare Foundation. “At present, only 12.9 million of the 34 million living with HIV/AIDS worldwide are on treatment. While 20X20 may seem like an ambitious goal, for both AHF and the world, it is one we believe we can achieve working together.”


When it began in 1987, AHF was the AIDS Hospice Foundation, and the main operational objective was to provide specialized hospice care for people living with AIDS, a disease that, at that time, was considered a death sentence. AHF advocated tirelessly for the rights of people suffering from HIV/AIDS to die with dignity and as little pain as possible in an accepting environment.

The Chris Brownlie Hospice opened on December 26, 1988 – the first specialized AIDS hospice in Los Angeles, named for one of the co-founders of AHF, writer and activist Chris Brownlie, who passed away from AIDS less than a year after the opening of that hospice. Two additional AHF hospices, Carl Bean House and Linn House, opened in 1992 and 1995, respectively.

As medical opportunities for managing HIV became more available, AHF changed its mission from providing compassionate care to people dying from HIV/AIDS to helping them live well with the disease through advanced medical care. This philosophical shift was marked with the change of the Foundation’s name to AIDS Healthcare Foundation in July 1990. The new focus on healthcare led to the founding of AHF Healthcare Centers, Wellness Centers, and the Positive Healthcare Network, the nation’s first capitated managed care program for people living with HIV.

In July 2000, AHF attended the International AIDS Conference in Durban, South Africa, where members of the Foundation joined with local partners and activists to provide testing to South Africans in Durban. The following year, AHF Global was established, and in 2002 the organization’s first healthcare clinic outside of the United States – the Ithembalabantu “People’s Hope” Clinic – opened in Durban, South Africa.

Today, in addition to its U.S. operations, which include running 41 health care centers in 13 states and the District of Columbia, operating 40 AHF Pharmacy outlets in 12 states, providing over 130,000 free HIV tests in 2013, running HIV-specific managed care programs in Florida and California, running 15 wellness centers in seven states offering free STD screenings, AHF also has operations in 35 other countries, including 222 additional AIDS treatment centers providing care around the globe. In 2013, AHF also distributed 33,800,892 free condoms worldwide and provided 1,944,681 free HIV tests around the globe.

About AHF

AIDS Healthcare Foundation (AHF) is the largest non-profit HIV/AIDS healthcare provider in the USA. AHF currently provides medical care and/or services to more than 350,000 individuals in 36 countries worldwide in the US, Africa, Latin America/Caribbean, Eastern Europe, and Asia. Additional information is available at www.aidshealth.org, find us on Facebook: www.facebook.com/aidshealth and follow us on Twitter & Instagram: @AIDSHealthcare

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50950465&lang=en


AIDS Healthcare Foundation

Ged Kenslea

Communications Director

+1.323.308.1833 (work)

+1.323.791.5526 (cell)


Terri Ford

Chief of Global Advocacy & Policy

+1.213.399.1001 (cell)

+1.323.308.1820 (work)


MoI Showcases its Children Protection Efforts at International Conference in Japan

Abu Dhabi, United Arab Emirates - Sunday, September 28th 2014 [ME NewsWire]

The Ministry of Interior showcased its child protection efforts during an international conference that recently concluded in Japan.

The Ministry of Interior’s experiences in the field of child protection were highly acclaimed by the attendees. Several delegations expressed their intention to enhance cooperation with the ministry and to get an overview of the latest developments in the UAE. These statements were made during a number of side meetings with the delegations of the United States, Canada, Australia, and the conference’s organizers.

The Ministry of Interior’s delegation took part in the XXth ISPCAN International Congress (International Society for the Prevention of Child Abuse and Neglect) that was held in the Japanese city of Nagoya from 14 to 17 September, under the theme “Towards child-centered societies: Learn from the past, act for the future”. This participation personifies the UAE’s vision and goal to become one of the safest places for children in the world.

Major Dr. Mohammed Khalifa Al Ali, Member and Rapporteur of the Higher Committee for Child Protection, Director of the Child Protection Initiative (Head of delegation), stressed that the participation is in response to the instructions of Major General Nasser Lakhrebani Al Nuaimi, Secretary General of the Office of HH Deputy Prime Minister and Minister of Interior, Chairman of the Higher Committee for Child Protection. It also embodies his keenness to participate in world conferences, which examine international efforts that aim to provide assistance and protection to children from the dangers they may encounter.

Major Al Ali noted that such participations boost international cooperation, which plays a significant role in transferring and exchanging knowledge, reviewing best practices, and identifying pioneering international initiatives and projects in this important area.

Adding further, he said that attending this conference provided the Ministry of Interior’s delegation with an opportunity to present and exchange viewpoints, ideas, and to showcase its practices and experiences in the area of child protection. “The conference shed light on the various entities and scientific disciplines that undertake similar roles. Creative ideas unfold through direct interaction at scientific conferences and meetings, as well as during the debates held on the sidelines of the conference,” Major Al Ali said.

Moreover, Major Al Ali noted that participation at such events contributes to keep abreast of all developments, establish relations and get acquainted with prominent figures that actively work in the child protection field.  This would promote cooperation between countries in a bid to provide protection and support to children, establish friendship ties between them, and unify all efforts to protect children against potential risks.

“During the four-day conference, the delegation gave three different presentations. In the first presentation, the delegation shed light on the training programs designed by the Ministry of Interior, to enhance awareness of individuals who work with children in kindergartens and schools. The second presentation gave an overview of the establishment and development of the Ministry of Interior’s Child Protection Center and highlighted the means of developing and implementing its strategy for child protection. The third presentation acquainted participants with the smartphone application “HEMAYATI”, designed by the Ministry of Interior as a tool to empower parents to protect their children. The delegation also distributed brochures to participants at the conference, highlighting the efforts exerted by the UAE Ministry of Interior in the area of child protection, and the means of using the application.

For more information about:

The Ministry of Interior, please click HERE

Abu Dhabi Police, please click HERE

Follow us and check our Social Media feeds on: YouTube, Facebook and Twitter

The Arabic-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the Arabic-language text, which is the only version of the text intended to have legal effect.

The UAE Minister of Interior's General Secretariat, Tactical Affairs and Security Media Department
Abu Dhabi Police GHQ - Security Media
Chris Cron +971-(0)-50-987-1317
E-mail: cron.media@hotmail.com

Permalink: http://me-newswire.net/news/12234/en

Sunday, September 28, 2014

AZD9291 Shows Durable Clinical Response in Patients with Advanced EGFR Mutation Positive Non-Small Cell Lung Cancer at the ESMO 2014 Congress

LONDON - Sunday, September 28th 2014 [ME NewsWire]

IMPRESS Study Results also Presented at the ESMO 2014 Congress Provide Increased Understanding of Treatment Options for Patients with EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer who have Developed Acquired Resistance to First Line IRESSA

LONDON--(BUSINESS WIRE)-- Updated data from the ongoing AURA study of AZD9291 shows encouraging, although still immature, median progression free survival of 9.6 months (95% CI 8.3 to NC) in patients with epidermal growth factor receptor mutation positive (EGFRm) T790M+ advanced non-small cell lung cancer (NSCLC) who had disease progression following treatment with an EGFR tyrosine kinase inhibitor (EGFR TKI).1 The progression free survival (PFS) results are based on a 30% data maturity from 138 patients.1

Data presented at the European Society for Medical Oncology (ESMO) 2014 Congress support and strengthen the results highlighted earlier this year at the American Society for Clinical Oncology (ASCO) Congress.

The ongoing AURA Phase I/II study is investigating AZD9291 in patients with advanced NSCLC.2 As of 1 August, 253 pre-treated patients have been dosed on this study and the 80 mg once daily dose has been selected for late stage development.1 The PFS results were coupled with a prolonged duration of response. In patients with EGFRm T790M+ advanced NSCLC treated at the 80 mg dose, the preliminary median duration of response was 8.2 months.1

James Chih-Hsin Yang, MD, PhD, professor of Graduate Institute of Oncology and Director of Cancer Research Center at National Taiwan University College of Medicine, said: “We are optimistic and encouraged by the rates of progression free survival and duration of response results in patients treated with AZD9291. While the data are still immature, they are based on robust patient numbers and this give us confidence that this is a trend that will continue. To date, the longest duration of response is still ongoing at more than 11 months.”

The confirmed overall response (ORR) rate for patients with EGFRm T790M+ advanced NSCLC treated at the 80 mg dose was 70 percent.1 For the 127 evaluable patients with EGFRm T790M+ advanced NSCLC treated at all doses, the confirmed ORR was 61 percent (78/127). As expected, patients with EGFRm T790M- advanced NSCLC had a lower confirmed ORR (21 percent; 13/61) and a shorter median PFS (2.8 months).1

The most common adverse events (AEs) in the AURA study at the 80 mg dose (N=90) were diarrhoea and rash, which were mostly mild (Grade 3 diarrhoea 1%; Grade 3 rash: 0%).1 Drug-related Grade 3 or greater AEs occurred in 10 patients (11%) treated at this dose, with no patients requiring dose reductions and one patient discontinuing medication due to a drug-related AE.1

The most common AEs at all doses (N=253) were diarrhoea and rash, which were mostly mild.1 Drug-related Grade 3 or greater AEs occurred in 33 patients (13%), with 17 patients requiring dose reductions (7%) and 7 patients (3%) discontinuing medication due to a drug-related AE.1

As of 12 September, more than 620 patients have been dosed with AZD9291 within the full clinical trial programme; pneumonitis-like events have been reported in approximately two percent of patients (13 events).1 Of these events, seven were Grade 1 or 2; three were Grade 3 and one Grade 5.1 Pneumonitis has been associated with both lung cancer itself, as well as available treatments for this disease.3,4

Results were also presented at the ESMO 2014 Congress on preliminary evidence of activity in NSCLC brain metastases5 and in first line patients with EGFRm NSCLC,6 supporting further investigation of AZD9291 in both of these settings.

In addition, data on the use of circulating tumour DNA (ctDNA), present in the plasma of NSCLC patients, as a predictive biomarker for response to AZD9291 were presented. There was a 65 percent response rate to treatment with AZD9291 at all dose levels in patients with T790M mutation detected using ctDNA in the AURA trial.7 ctDNA may offer an attractive alternative for a non-invasive test to provide tumour genotyping in patients unable to supply evaluable tumour samples at biopsy or rebiopsy following first line EGFR-TKI failure. IRESSA® (gefitinib) recently became the first EGFR-TKI in Europe to have a label allowing the use of ctDNA for the assessment of EGFRm status in those patients where a tumour sample is not evaluable.8

AstraZeneca has initiated both Phase II and Phase III studies in patients with EGFRm T790M+ advanced NSCLC who had disease progression following treatment with an EGFR TKI (AURA 29 and AURA 310 respectively). In addition, a Phase III study evaluating AZD9291 in first line EGFRm advanced NSCLC is scheduled to start later this year.

AstraZeneca is also currently investigating the combination of AZD9291 with MEDI4736 (PDL-1 immunotherapy), selumetinib (small molecule MEK inhibitor) and AZD6094 (small molecule MET inhibitor) in NSCLC.11

Antoine Yver, Head of Oncology, Global Medicines Development, AstraZeneca, said: “The AZD9291 data at the ESMO 2014 Congress reinforce the clinical activity results presented at ASCO for this investigative therapy and continue to demonstrate how diagnostic-led treatments could improve patient care. AstraZeneca is focused on developing novel treatments that address the genetic drivers underlying lung cancer as well as overcoming its resistance mechanisms. For over 40 years AstraZeneca has delivered innovative drugs to improve the available options for cancer patients, including IRESSA, the first targeted therapy for patients with EGFRm advanced NSCLC.”

AstraZeneca also presented data from the investigational Phase III IMPRESS study at the ESMO 2014 Congress. The study was a second line, combination study in patients with EGFRm advanced NSCLC who have acquired resistance to first line IRESSA.12

The IMPRESS study was designed to compare the efficacy and safety of continuing IRESSA, combined with cisplatin and pemetrexed up to six cycles (no pemetrexed maintenance), versus comparator placebo, combined with cisplatin and pemetrexed up to six cycles (no pemetrexed maintenance) following the development of resistance to first line treatment gefitinib.12

The study did not meet its primary endpoint of a statistically significant improvement in PFS.12 The secondary endpoint of overall survival (OS) is still ongoing. At the primary endpoint of PFS analysis, the OS was immature (33% of events) and was not conclusive. Longer OS was suggested for the placebo plus cisplatin and pemetrexed arm, versus the IRESSA plus cisplatin and pemetrexed arm.12 Overall, IRESSA combined with cisplatin plus pemetrexed chemotherapy was well tolerated and in line with known safety profiles.12

The IMPRESS results answer an important scientific question regarding the effectiveness of a treatment strategy that includes IRESSA in second line, in combination with cisplatin and pemetrexed in patients who have acquired resistance to IRESSA.

AstraZeneca is continuing to explore several treatment strategies with IRESSA, including the recent initiation of Phase I trials exploring the combination of IRESSA with MEDI4736 (PDL-1 immunotherapy),13 tremelimumab (CTLA-4 immunotherapy)14 and selumetinib (small molecule MEK inhibitor).15


About the AURA study

The AURA Phase I/II trial, is an ongoing, open label, dose escalation and expansion cohort study to investigate the safety and tolerability, pharmacokinetics, response to therapy and adverse events of AZD9291 in patients with advanced NSCLC who had disease progression following treatment with an EGFR TKI.2 As of 1 August 2014, in the ongoing AURA study, 253 pre-treated patients have been dosed with AZD9291 capsule and of these, 239 have been evaluable for confirmed response.1

About AZD9291

AZD9291 is an investigational, highly selective, irreversible inhibitor of both activating sensitising EGFRm and the resistance mutation, T790M, while sparing the activity of wild type EGFR.16 AZD9291 is also designed to achieve minimal or no activity against two biological receptors, known as the insulin receptor and insulin-like growth factor receptor (IFGR), in order to avoid the potential for hyperglycaemia.17 Hyperglycaemia (high blood sugar) can lead to patients requiring treatment with additional medications.17

Patients who have the EGFRm form of NSCLC, which occurs in 10-15 percent of NSCLC patients in Europe18 and 30-40 percent of NSCLC patients in Asia19, are particularly sensitive to treatment with currently available EGFR TKIs, which block the cell signalling pathways that drive the growth of tumour cells.20-22 However, tumour cells almost always develop resistance to treatment, leading to disease progression. In more than half of patients with EGFRm advanced NSCLC, this resistance is caused by a secondary mutation known as T790M.23 There are currently no treatments specifically approved specifically for EGFRm T790M+ advanced NSCLC.

AZD9291 has been granted been granted Breakthrough Therapy designation, Orphan Drug and Fast Track status by the US Food and Drug Administration (FDA). AstraZeneca anticipates filing for regulatory approval in the US in the second half of 2015.


IRESSA is an EGFR TKI that blocks the signals from the EGFR, which leads to tumour growth. EGFR is a protein found in abnormally high levels on the surface of many types of cancer cells, particularly NSCLC cells.

IRESSA was launched in 2009 and is now approved in 89 countries worldwide.

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com.


1 Yang, J, et al. Updated safety and efficacy from a Phase 1 study of AZD9291 in patients (pts) with EGFR-TKI-resistant non-small cell lung cancer (NSCLC). Presented at European Society for Medical Oncology (ESMO) Annual Meeting, Madrid; 26-30 September 2014. Abstract available at: https://www.webges.com/cslide/library/esmo/browse/search/bjy#9f9C033w. Accessed September 2014.

2 National Institutes of Health. AZD9291 First Time In Patients Ascending Dose Study (AURA). Available: http://www.clinicaltrials.gov/ct2/show/NCT01802632?term=AURA+AZD9291&rank=1. Accessed September 2014.

3 Archontogeorgis K, et al. Lung Cancer and Interstitial Lung Diseases: A Systematic Review. Pulmonary Medicine 2012;2012:315918.

4 Qi WX, et al. Risk of interstitial lung disease associated with EGFR-TKIs in advanced non-small-cell lung cancer: a meta-analysis of 24 phase III clinical trials. J Chemother. 2014 Apr 14:1973947814Y0000000189. [Epub ahead of print].

5 Kim DW, et al. Preclinical evidence and clinical cases of AZD9291 activity in EGFR-mutant non-small cell lung cancer (NSCLC) brain metastases (BM). Presented at European Society for Medical Oncology (ESMO) Annual Meeting, Madrid; 26-30 September 2014. Abstract available: https://www.webges.com/cslide/library/esmo/browse/search/bkN#9faC031K. Accessed September 2014.

6 Ramalingam S, et al. Pre-clinical and clinical evaluation of AZD9291, a mutation-specific inhibitor, in treatment-naïve EGFR-mutated NSCLC. Presented at European Society for Medical Oncology (ESMO) Annual Meeting, Madrid; 26-30 September 2014. Abstract available: https://www.webges.com/cslide/library/esmo/browse/search/bkf#9faC03fF. Accessed September 2014.

7 Thress KS, et al. Levels of EGFR T790M in plasma DNA as a predictive biomarker for response to AZD9291, a mutant-selective EGFR kinase inhibitor. Presented at European Society for Medical Oncology (ESMO) Annual Meeting, Madrid; 26-30 September 2014. Abstract available at: https://www.webges.com/cslide/library/esmo/browse/search/ctV#9faC036N. Accessed September 2014.

8 IRESSA Receives CHMP positive opinion to include blood based diagnostic testing in European label. Press release to be issued on Thursday, 25 September 2014.

9 National Institutes of Health. Phase II AZD9291 Open Label Study in NSCLC After Previous EGFR TKI Therapy in EGFR and T790M Mutation Positive Tumours. Available at:http://clinicaltrials.gov/ct2/show/NCT02094261?term=AURA+2&rank=1. Accessed September 2014.

10 National Institutes of Health. AZD9291 Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer. Available at:http://clinicaltrials.gov/ct2/show/NCT02151981?term=AURA+3&rank=1. Accessed September 2014.

11 National Institutes of Health. AZD9291 in Combination With Ascending Doses of Novel Therapeutics. Available at: https://clinicaltrials.gov/ct2/show/NCT02143466?term=azd9291&rank=1. Accessed September 2014.

12 Mok TSK, et al. Gefitinib/chemotherapy vs chemotherapy in epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC) after progression on first-line gefitinib: the Phase III, randomised IMPRESS study. Presented at European Society for Medical Oncology (ESMO) Annual Meeting, Madrid; 26-30 September 2014.

13 National Institutes of Health. MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer (NSCLC). Available:https://clinicaltrials.gov/ct2/show/NCT02088112?term=%22gefitinib%22+and+%22combination%22+and+%22lung%22&rank=12. Accessed September 2014.

14 National Institutes of Health. Tolerability and Efficacy of Tremelimumab in Combination With Gefitinib in NSCLC Patients (GEFTREM). Available:https://clinicaltrials.gov/ct2/show/NCT02040064?term=%22gefitinib%22+and+%22combination%22+and+%22lung%22&rank=17. Accessed September 2014.

15 National Institutes of Health. Selumetinib in Combination With Gefitinib in NSCLC Patients. Available: https://clinicaltrials.gov/ct2/show/NCT02025114?term=%22gefitinib%22+and+%22combination%22+and+%22lung%22&rank=23. Accessed September 2014.

16 Cross DA, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014;4:1046-61.

17 Pollack M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer. 2008:8; 915-928.

18 Szumera-Ciećkiewicz A, et al. EGFR mutation testing on cytological and histological samples in non-small cell lung cancer: a Polish, single institution study and systematic review of European incidence. Int J Clin Exp Pathol. 2013;6:2800-12.

19 Ellison G, et al. EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples. J Clin Pathol. 2013;66:79-89.

20 Sharma SV, et al. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007;7:169-81.

21 Mok TS, et al. Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma. N Engl J Med. 2009;361:947-57.

22 Rosell R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13:239–46.

23 Yu H, et al, Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers. Clin Cancer Res. 2013:19:2240-7.



Anthonia Aboyeji, +44 (0)788 473 1627


Ayesha Bharmal, +44 (0)782 408 2209


Esra Erkal-Paler +44 (0)207 604 8030

Oral OTEZLA® (apremilast) Approved by the U.S. Food and Drug Administration for the Treatment of Patients with Moderate to Severe Plaque Psoriasis

ME NewsWire/Business Wire

SUMMIT, N.J. - Saturday, September 27th 2014

In phase III studies, OTEZLA resulted in significant and clinically meaningful improvements in plaque psoriasis

OTEZLA demonstrated a consistent safety and tolerability profile across clinical trials

Celgene Corporation (NASDAQ: CELG) today announced that the U.S. Food and Drug Administration (FDA) has approved OTEZLA® (apremilast), the Company’s oral, selective inhibitor of phosphodiesterase 4 (PDE4), for the treatment of patients with moderate to severe plaque psoriasis for whom phototherapy or systemic therapy is appropriate. OTEZLA is the first and only PDE4 inhibitor approved for the treatment of plaque psoriasis. Psoriasis, a chronic inflammatory disease of the skin resulting from an uncontrolled immune response, affects more than 125 million people worldwide.

“OTEZLA offers an important new treatment option for patients whose symptoms are not adequately improving with their current treatments. In clinical trials, OTEZLA reduced redness, thickness, and scaliness of plaques in patients with moderate or severe plaque psoriasis,” said Dr. M. Shane Chapman, Section Chief of Dermatology at Dartmouth-Hitchcock Medical Center. “Because the product labeling does not require routine laboratory monitoring, oral OTEZLA may be a welcome new option for patients and physicians looking for a different treatment experience.”

The approval of OTEZLA was based primarily on safety and efficacy results from two multi-center, randomized, double-blind, placebo-controlled studies – ESTEEM 1 and ESTEEM 2 – conducted in adult patients with moderate to severe plaque psoriasis: body surface area (BSA) involvement of ≥10%, static Physician Global Assessment (sPGA) of ≥3 (moderate or severe disease), Psoriasis Area and Severity Index (PASI) score ≥12, and candidates for phototherapy or systemic therapy.

“OTEZLA offers a valuable treatment option for a spectrum of plaque psoriasis patients – patients who are treatment-naïve as well as patients who are treatment-experienced, including those previously treated with biologic agents or conventional systemic agents,” said Scott Smith, President Inflammation & Immunology for Celgene Corporation. “The FDA approval of OTEZLA for plaque psoriasis, together with the previous approval for psoriatic arthritis, reflects Celgene’s commitment to extending the reach of our research and science in an effort to improve the lives of people worldwide living with chronic inflammatory diseases.”

In the ESTEEM studies, OTEZLA treatment resulted in significant and clinically meaningful improvements in plaque psoriasis as measured by PASI scores at week 16. Clinical improvement as measured by sPGA scores of clear to almost clear were also demonstrated in both studies.

The safety of OTEZLA was assessed in 1,426 patients from three clinical trials. Side effects of OTEZLA were diarrhea, nausea, upper respiratory tract infection, tension headache, and headache. Before starting OTEZLA, patients should inform their doctor if they have a history of depression or suicidal behavior and if these conditions or other mood changes develop or worsen while taking OTEZLA. Patients taking OTEZLA should have their weight checked regularly.

“Psoriasis is a serious autoimmune disorder commonly associated with comorbidities,” said Randy Beranek, president and CEO, National Psoriasis Foundation. “Effectively treating psoriasis is an important part of managing a patient's overall health. Having a new treatment like OTEZLA is important so patients can have more options and can work closely with their providers to find what works best for them.”

OTEZLA® is available in the U.S. and is dispensed through a comprehensive network of specialty pharmacies. For more information about OTEZLA distribution and the exclusive treatment support services (including reimbursement assistance and 24/7 nurse support), doctors and patients can contact Otezla SupportPlus™ at 1-844-4OTEZLA (1-844-468-3952) or visit www.OTEZLA.com for more information.

OTEZLA was approved on March 21, 2014 by the U.S. Food and Drug Administration (FDA) for the treatment of adults with active psoriatic arthritis. A New Drug Submission (NDS) for psoriatic arthritis was submitted to health authorities in Canada in the second quarter of 2013. A NDS for psoriasis in Canada as well as a combined psoriatic arthritis/psoriasis Marketing Authorization Application (MAA) in Europe were all submitted to health authorities in the fourth quarter of 2013.

Note to editors: Additional information can be found at http://smp.businesswire.com/pages/oral-otezla-apremilast-approved-us-food-and-drug-administration-treatment-patients-moderate.


ESTEEM 1 and 2 are two large pivotal phase III randomized, placebo-controlled studies evaluating OTEZLA in patients with a diagnosis of moderate to severe plaque psoriasis for at least 12 months prior to screening, and who were also candidates for phototherapy and/or systemic therapy. Approximately 1,250 patients were randomized 2:1 to receive either OTEZLA 30 mg twice daily or placebo after an initial five-day titration period, for the first 16 weeks, followed by a maintenance phase from weeks 16-32 in which placebo patients were switched to OTEZLA 30 mg twice daily through week 32, and a randomized withdrawal phase for responders from week 32 to week 52 based on their initial OTEZLA randomization and PASI-75 response.


OTEZLA is an oral small-molecule inhibitor of phosphodiesterase 4 (PDE4) specific for cyclic adenosine monophosphate (cAMP). PDE4 inhibition results in increased intracellular cAMP levels which is thought to indirectly modulate the production of inflammatory mediators. The specific mechanism(s) by which OTEZLA exerts its therapeutic action in patients with psoriasis or psoriatic arthritis is not well defined.


OTEZLA® (apremilast) is indicated for the treatment of patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.

OTEZLA is also indicated for the treatment of adult patients with active psoriatic arthritis.


Patients who are allergic to apremilast or to any of the ingredients in OTEZLA should not take OTEZLA. Certain medicines should not be taken when on OTEZLA as they may decrease its effectiveness. Patients should tell their doctor about all the medicines they take, including prescription and nonprescription medicines. Women should inform their doctor if they are pregnant, planning to become pregnant, or planning to breastfeed. OTEZLA has not been studied in pregnant women or in women who are breastfeeding. These are not all the possible side effects with OTEZLA. Patients should ask their doctor about other potential side effects and tell their doctor about any side effect that bothers them or does not go away.

Patients are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-332-1088.

Please click here for Full Prescribing Information.

About Psoriasis

Psoriasis is an immune-mediated, non-contagious chronic inflammatory skin disorder of unknown cause. The disorder is a chronic recurring condition which varies in severity from minor localized patches to complete body coverage. Plaque psoriasis is the most common type of psoriasis. About 80 percent of people who develop psoriasis have plaque psoriasis, which appears as patches of raised, reddish skin covered by silvery-white scales. These patches, or plaques, frequently form on the elbows, knees, lower back, and scalp. Psoriasis occurs nearly equally in males and females. An estimated 125 million people worldwide have psoriasis. To learn more about the role of PDE4 in inflammatory diseases, go to www.discoverpde4.com.

About Celgene

Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global pharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. For more information, please visit www.celgene.com.

Forward-Looking Statements

This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words “expects,” “anticipates,” “believes,” “intends,” “estimates,” “plans,” “will,” “outlook” and similar expressions. Forward-looking statements are based on management’s current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, many of which are discussed in more detail in our Annual Report on Form 10-K and other reports filed with the Securities and Exchange Commission.


Celgene Corporation


Patrick E. Flanigan III, 908-673-9969

Vice President, Investor Relations


Catherine Cantone, 732-564-3592

Director, Corporate Communications

Permalink: http://www.me-newswire.net/news/12232/en

ZeroChaos Releases 3rd Generation of ZC Mobile

The 3rd generation of ZC Mobile, the mobile version of the ZC Web vendor management system, is now available on Google Play and the App Store

ORLANDO, Fla. - Thursday, September 25th 2014 [ME NewsWire]

(BUSINESS WIRE) -- In the 3rd generation release of ZC Mobile, ZeroChaos has extended and enhanced the usability and functionality of its app even further for their Apple and Android users, globally.

Vendor management systems are tools that help companies manage their outside labor and service vendors. “ZeroChaos knows that for its audiences of customers, staffing suppliers, and contract resources, work doesn’t end at their desk. That’s why our focus since 2011 has been to enable our customers anytime, anywhere they may be,” says Gary Flowers, CIO of ZeroChaos.

The third generation of ZC Mobile offers broad functionality, including:

    Enhanced requisition and timesheet management
    Supplier remittance and resource pay statements
    Maintaining dossier information including language and currency preferences
    Managing surrogates and more

The latest version of ZC Mobile is available immediately and is free to download from Google Play and the App Store.

About ZeroChaos

Headquartered in Orlando, Florida; ZeroChaos is the world’s largest vendor-neutral managed services provider. Since 1999 we have been helping companies rethink their contingent workforce strategies to achieve greater quality, process efficiency, and cost containment. Built on innovation, our solutions are at work in over 97 countries across the globe, successfully serving a variety of clients. Our services and products include Managed Services Programs, Vendor Management Systems, Compliance and Risk Mitigation, Background Screening, Private Label Sourcing, and Professional Payroll Services.



John Cloonan, 407-233-5826


Permalink: http://www.me-newswire.net/news/12218/en

Tory Burch Names Roger Farah Co-Chief Executive Officer

– Tory Burch and Roger Farah Form Executive Directors Office to Oversee the Company’s Global Growth Strategy –

NEW YORK - Thursday, September 25th 2014 [ME NewsWire]

(BUSINESS WIRE) -- Tory Burch, LLC, today announced it has named Roger Farah co-Chief Executive Officer. Mr. Farah and Ms. Burch will also establish an Executive Directors Office (EDO), a newly formed management group made up of Brigitte Kleine, Robert Isen, Roger Farah and Tory Burch to lead and oversee the management of the company. Ms. Kleine will remain President of Tory Burch, LLC and will join the Board of Directors. Mr. Farah has also been appointed to the Board of Directors. Ms. Burch will retain her role as Chairman of the Board. Mr. Isen will retain his role as a member of the Board and continues as President of Business Development and Chief Legal Officer.

Mr. Farah’s previous experience with large international brands will strategically complement the business in its ongoing global expansion. The EDO will streamline the decision making process, enabling the company to quickly and thoughtfully execute strategic opportunities.

“We have grown significantly over the last ten years and Roger is uniquely qualified to help us continue to build and scale the business. He is an exceptional person and one of the great executives in our industry,” said Tory Burch, Chairman and co-CEO of Tory Burch, LLC. “This is an exciting moment for the company and Brigitte, Robert and I look forward to working with him.”

Mr. Farah spent fourteen years at Ralph Lauren as President and Chief Operations Officer. He joined Ralph Lauren from Venator Group, Inc. in 2000 where he was as Chairman and CEO from 1994 to 2000. He previously served as the President and COO of Macy’s Inc. and Chairman and CEO of Federated Merchandising Services and Rich’s Department Stores.

“The opportunity to join a growing, privately held, values-based company like Tory Burch was very appealing,” said Mr. Farah. “I’ve admired Tory for a long time and look forward to partnering with her and her team to execute her long-term vision.”

The company currently has 136 stores worldwide including a recently opened Shanghai flagship and has announced plans to open additional flagships in Milan, Paris and Soho, NY. The company’s recent partnerships include a successful beauty launch with Estee Lauder and upcoming watch launch with Fossil. It has also announced new distribution plans for Indonesia and Malaysia.

About Tory Burch:

Tory Burch is an iconic American brand that embodies the personal style and sensibility of its CEO and designer, Tory Burch. Launched in February 2004, the collection consists of ready-to-wear, shoes, handbags, accessories, and fragrance and beauty. There are 136 Tory Burch boutiques across North America, Europe, the Middle East, Latin America and Asia, and the brand is available at over 3,000 department and specialty stores worldwide and toryburch.com.



Tory Burch, LLC

Frances Pennington, 646-723-6629

SVP Global PR & Brand Communications


Permalink: http://me-newswire.net/news/12216/en

Mavenir Systems® Enables Service Providers to Disrupt OTT Services

RICHARDSON, Texas - Friday, September 26th 2014 [ME NewsWire]

(BUSINESS WIRE) -- Mavenir Systems® (NYSE:MVNR), a leading provider of software-based networking solutions, announced today that its 4G LTE software solutions enable mobile operators to disrupt OTT applications by leveraging Voice over LTE (VoLTE) and launch innovative new services such as HD Voice, Wi-Fi Calling and Video Calling, that are natively supported on the latest generation of 4G LTE devices.

“Multiple smartphone vendors, such as Samsung and Apple, are introducing new devices that natively support the advanced services enabled by our technology,” said Pardeep Kohli, President and Chief Executive Officer, Mavenir Systems. “This is a key milestone in a maturing 4G LTE device ecosystem that will embolden mobile operators to compete with and disrupt popular OTT service providers.”

A second disruptive element is the introduction of seamless mobility as a new feature on the latest devices, such as Apple’s iPhone 6, that ensures services aren’t interrupted as users move between LTE coverage areas and Wi-Fi hotspots. For example, seamless mobility ensures that voice calls established using Wi-Fi access while at home, in the office or at a coffee shop will seamlessly handover to the LTE network, or vice versa, and remain active.

Mavenir™ supports this new feature with its recently announced evolved Packet Data Gateway (ePDG), as well as its deep expertise in mobility, having previously provided alternative solutions to our customers based on Universal Mobile Access (UMA) and Voice Call Continuity (VCC) technologies.

A third disruptive element is the introduction of new services across a multi-device ecosystem of smartphones, tablets and PCs, as leading operators look for ways to further monetize their investments in VoLTE. Mobile operator business models will leverage VoLTE as an IP Cloud to enable any service to work on any device from any access network, which is an experience that until now has only been possible using OTT services such as Skype. Mavenir’s OTT client is now available for both Android™ and iOS platforms and provides capability for Voice, Video and RCS applications.

“As long as a subscriber has access to the public Internet, rich IP services can be accessed from anywhere in the world, removing boundaries historically imposed by technology, device and geography,” added Kohli.

Apple’s recent announcements that VoLTE and Wi-Fi Calling will be supported on the iPhone 6 and in iOS 8 is an indication that momentum for VoLTE is building. Major operators in key markets, such as Verizon, AT&T and T-Mobile in the United States, have already launched VoLTE. There is an opportunity for an innovative operator to leapfrog other operators in the market and differentiate themselves.

Mavenir’s suite of IP core networking solutions are based on a portfolio of over 30 software products that are fully virtualized and can be deployed on cloud-based infrastructure and within an NFV framework. Leading mobile operators such as T-Mobile USA have deployed Mavenir's converged IMS-based solution to successfully launch VoLTE and Wi-Fi Calling services with the scale and reliability needed to become mass market mobile services.

About Mavenir

Mavenir Systems (NYSE: MVNR) provides software-based networking solutions that enable mobile service providers to deliver next generation services over 4G LTE networks. Mavenir™ has a fully virtualized end to end portfolio of Voice/Video, Messaging and Mobile Core products that include IP Multimedia Subsystem (IMS), Evolved Packet Core (EPC) and Session Border Controller (SBC). Mavenir's solutions, based on the award-winning mOne® software platform, leverage NFV and SDN technologies for deployments on cloud-based infrastructure.

© 2014 Mavenir Systems, Inc. All rights reserved. Mavenir Systems®, mOne®, AirMessenger®, Mavenir™, mStore™, mCloud™, and Transforming Mobile Networks™ are trademarks of Mavenir Systems, Inc.

iPhone, iPhone 6, iPhone 6 Plus are registered marks of Apple Inc.


Mavenir Systems, Inc.

Maryvonne Tubb/Katie Caballero, +1-469-916-4393


Permalink: http://www.me-newswire.net/news/12228/en

BlackBerry Passport with SlimPort is the Prosumers Ticket to Mobile Productivity

Professionals on the Go Can Share Multimedia and Virtual Paperwork on Projectors and Monitors for Ultimate Productivity

ANTA CLARA, Calif - Thursday, September 25th 2014 [ME NewsWire]

(BUSINESS WIRE) -- Analogix Semiconductor, Inc. announced that the newly released BlackBerry Passport features a built-in SlimPort® interface solution, which allows it to connect to boardroom projectors and large screen displays for a seamless high-definition viewing experience.

Designed from the ground up with the working professional in mind, the BlackBerry Passport with its 1,440 x 1,440 4.5-inch screen provides more viewing area for spreadsheets and data and features the same resolution as Full HD-equipped phablets. SlimPort display-out further expands the smartphone’s usefulness in the work environment, increasing user productivity and enabling a collaborative working experience through an easy, fast and reliable high resolution connection between the phone and the big screen.

An impressive 3,450 mAh battery backs up all the conference calls, emails and browsing one can do in a day and a touch-enabled physical keyboard comes handy for emails, blog posts, messages, and editing documents and presentations. Today’s professionals are managing more and more content on the go and smart connectivity is at the center of it all.

“We’re proud that BlackBerry has chosen SlimPort for its latest flagship phone. Bigger crowds call for bigger screens and SlimPort enables BlackBerry Passport users to share their multimedia and data with colleagues on a projector during boardroom meetings or on a monitor while at their desk,” said Andre Bouwer, vice president of marketing for Analogix.

About Analogix Semiconductor

Analogix Semiconductor, Inc. designs and manufactures semiconductors for the digital multimedia market, from portable devices such as smartphones to high-end graphics cards and large, high-definition displays. Analogix is the market leader in providing end-to-end interface connectivity semiconductor solutions for DisplayPort, including the SlimPort family of products, and an industry leader in mobile display controllers, such as low-power, high-speed timing controller solutions. The DisplayPort standard is an innovative, packetized digital interface for high-resolution video and audio that was developed by the Video Electronics Standards Association (VESA). SlimPort branded products are compliant with the DisplayPort and the Mobility DisplayPort (MyDP) standard.

For more information visit www.analogix.com and www.slimportconnect.com or follow us on Twitter @Analogix and @SlimPortConnect.

Analogix and SlimPort are trademarks or registered trademarks of Analogix Semiconductor, Inc. All other trademarks and trade names are the property of their respective owners.

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50949649&lang=en


Analogix Media Contact

Gratia Stefan, 408-988-8848


Permalink: http://www.me-newswire.net/news/12211/en

Edwards Joins AFL as EMEA President

SPARTANBURG, S.C - Thursday, September 25th 2014 [ME NewsWire]
(BUSINESS WIRE) AFL, a global provider of fiber optic solutions, announces that Phil Edwards has joined AFL as president of EMEA (Europe, Middle East, Africa). Edwards will be responsible for leading AFL’s business strategy and operations in the EMEA region, and building the infrastructure needed to support growth for AFL.
“AFL recognizes a tremendous opportunity to build our business in the EMEA region. Bringing Phil on board adds a proven leader to our team, and positions us to take full advantage of the market opportunities. His background and experiences in telecom industry is truly impressive and I am pleased to have Phil join our leadership team,” said Jody Gallagher, president and CEO of AFL.
Edwards served as the Group President of Draka Communications at Draka Holding N.V. prior to its merger with Prysmian Group in 2011 when he was appointed to the position of Executive Vice President of Telecom Business at Prysmian S.p.A.
“With AFL’s diverse product portfolio, proven expertise in fiber optics and consistent record of profitable growth, I know AFL is well positioned to maximize its presence in EMEA. I am excited to join the AFL team and look forward to bringing unique solutions to customers in our region,” added Phil Edwards, president of EMEA for AFL.
Edwards is a graduate of Swansea University in the United Kingdom where he earned a Bachelor of Science degree in Mathematics and Physics.
For additional information about AFL, its products and services, visit www.AFLglobal.com.
About AFL
AFL provides industry-leading products and services to the electric utility, broadband, communications, enterprise and OEM markets as well as the emerging markets of oil and gas, mining, nuclear, avionics, renewables and transportation. The company’s diverse product portfolio includes fiber optic cable, transmission and substation accessories, outside plant equipment, connectors, fusion splicers, test equipment and training. AFL’s service portfolio includes market-leading positions with the foremost communications companies supporting inside plant central office, EF&I, outside plant, enterprise and wireless areas.
Founded in 1984, AFL is proud to offer engineering expertise, exceptional products and reliable service that help our customers improve their critical and electrical infrastructure. AFL has operations in the U.S., Mexico, Canada, Europe, Asia and the South Pacific. The company is headquartered in Spartanburg, SC and is a wholly-owned subsidiary of Fujikura Ltd. of Japan. For more information, visit www.AFLglobal.com.
Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50949160&lang=en

Corie Culp, 864-433-5409
Public Relations Manager

Permalink: http://me-newswire.net/news/12209/en

Nintedanib* Receives Positive CHMP Opinion for Second-Line Treatment of Patients with Adenocarcinoma of the Lung

INGELHEIM, Germany. - Friday, September 26th 2014 [ME NewsWire]

• Nintedanib*, when added to docetaxel, is the first lung cancer treatment to have provided over one year overall survival for patients with advanced adenocarcinoma, after first-line chemotherapy

• Adenocarcinoma is the most common type of lung cancer and nintedanib* has demonstrated the first advancement in overall survival benefit for this patient population in over a decade

(BUSINESS WIRE)-- For media outside UK and US only

Boehringer Ingelheim today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for the approval of nintedanib* (suggested brand name Vargatef®) in combination with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology after first-line chemotherapy.

Adenocarcinoma is the most common type of lung cancer and accounts for nearly half of all NSCLC cases. The majority of patients with advanced adenocarcinoma will experience disease progression after first-line chemotherapy and there is still a significant unmet need for new, effective second-line treatments for these patients who have a poor prognosis.

“We are delighted to receive this positive opinion from the CHMP”, said Professor Klaus Dugi, Chief Medical Officer, Boehringer Ingelheim. “Nintedanib, a triple angiokinase inhibitor, when added to docetaxel, provided adenocarcinoma patients with a median overall survival of over one year, a benefit which has not been achieved before.”

The CHMP opinion is based on the outcomes of the LUME-Lung 1 clinical trial. The results showed that compared to docetaxel alone, nintedanib* plus docetaxel significantly extended the median overall survival from 10.3 to 12.6 months for patients with advanced adenocarcinoma, after first-line chemotherapy (p=0.0359; HR: 0.83).

The additional benefit nintedanib* provided to adenocarcinoma patients was achieved without nintedanib* further impacting their quality of life. Most common adverse events (AEs) for patients taking nintedanib* plus docetaxel were gastro-intestinal side effects and reversible liver enzyme elevations which were manageable by either supportive treatment or dose reduction.

“Patients with advanced adenocarcinoma NSCLC after first-line chemotherapy typically have a very poor prognosis. Therefore, providing an extension of overall survival while maintaining quality of life remains the ultimate goal”, commented PD. Dr Martin Reck, Head of Department of Thoracic Oncology, Lung Clinic Grosshansdorf, Germany. “Nintedanib has shown promise in achieving this by prolonging the overall survival beyond the one year barrier in second-line adenocarcinoma NSCLC patients.”

Nintedanib* is the second compound in the Boehringer Ingelheim oncology portfolio after afatinib** (GIOTRIF®/GILOTRIF®) which is approved to treat lung cancer patients with distinct types of NSCLC.

Please click on the link below for ‘Notes to Editors’ and ‘References’:


*Nintedanib is an investigational compound and is not yet approved. Its safety and efficacy have not yet been fully established.

**Afatinib (GIOTRIF® / GILOTRIF®) is indicated for the treatment of distinct types of EGFR mutation-positive NSCLC. In this indication, afatinib is approved in a number of markets, including the EU, Japan, Taiwan and Canada under the brand name GIOTRIF® and in the U.S. under the brand name GILOTRIF®. It is under regulatory review in other countries. Afatinib is not approved in other indications.

Further Media Channels:








Boehringer Ingelheim

Arnd Prilipp

Corporate Communications

Media + PR

Phone: +49 6132 – 77 2091

Fax: +49 6132 – 77 6601

Email: press@boehringer-ingelheim.com